{
    "id": "0334",
    "question": "A 51-year-old woman was recently diagnosed with type II diabetes. Due to the cumulative effects of diabetes, various health screenings and vaccinations are routinely recommended. Which of the following vaccinations or screening measures are recommended in patients with diabetes?",
    "options": {
        "A": "Urinalysis every 6 months",
        "B": "Comprehensive foot exam every year",
        "C": "Weekly foot inspections by patient or family member",
        "D": "Meningococcal vaccine"
    },
    "answer": "B",
    "predict": "Here's the step-by-step thinking and the answer in JSON format: {\"step_by_step_thinking\": \"The question is asking about routine health screenings and vaccinations recommended for a 51-year-old woman with type II diabetes. According to the provided documents, patients with diabetes are recommended for various screenings and vaccinations to prevent complications and related health issues. We need to identify the correct option from the given choices. Let's analyze each option: \\n\\n Option A: Urinalysis every 6 months - There is no specific recommendation for urinalysis frequency in patients with diabetes. However, microalbuminuria should be detected at an early stage when effective therapies can be instituted, and screening for microalbuminuria should be performed in patients with type 1 diabetes for \u22655 years, in patients with type 2 diabetes, and during pregnancy. \\n\\n Option B: Comprehensive foot exam every year - This is a recommended practice for patients with diabetes to prevent foot ulcers and amputations. The optimal therapy for foot ulcers and amputations is prevention through identification of high-risk patients, education of the patient, and institution of measures to prevent ulceration. High-risk patients should be identified during the routine, annual foot examination performed on all patients with DM. \\n\\n Option C: Weekly foot inspections by patient or family member - While foot inspections are recommended, there is no specific recommendation for weekly inspections. The monofilament test or one of the other tests is abnormal, the patient is diagnosed with loss of protective sensation (LOPS). \\n\\n Option D: Meningococcal vaccine - The flu vaccine is administered every fall, and the pneumococcal vaccine is recommended every 6 years. There is no specific recommendation for the meningococcal vaccine. \\n\\n Based on the analysis, the correct answer is B. Comprehensive foot exam every year, as it is a recommended practice for patients with diabetes to prevent foot ulcers and amputations.\"} {\"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_27765",
            "title": "InternalMed_Harrison",
            "content": "Widespread use of the FPG or the HbA1c as a screening test for type 2 DM is recommended because (1) a large number of individuals who meet the current criteria for DM are asymptomatic and unaware that they have the disorder, (2) epidemiologic studies suggest that type 2 DM may be present for up to a decade before diagnosis, (3) some individuals with type 2 DM have one or more diabetes-specific complications at the time of their diagnosis, (4) treatment of type 2 DM may favorably alter the natural history of DM, diagnosis of prediabetes should spur efforts for diabetes prevention. The ADA recommends screening all individuals >45 years every 3 years and screening individuals at an earlier age if they are overweight (BMI >25 kg/m2 or ethnically relevant definition for overweight) and have one additional risk factor for diabetes (Table 417-3). In contrast to type 2 DM, a long asymptomatic period of hyperglycemia is rare prior to the diagnosis of type 1 DM. A number of immunologic markers"
        },
        {
            "id": "Gynecology_Novak_906",
            "title": "Gynecology_Novak",
            "content": "If the HgA1C is <7% or the postprandial glucose is <200 mg/dL, omit the oral hypoglycemic agents, place on diet alone, and follow every 3 months. If the fasting serum glucose is >200 mg/dL consistently or the HgA1C is more than 10%, consider starting insulin and referring the patient to an internist. Administer the \ufb02u vaccine every fall and the pneumococcal vaccine every 6 years. ADA, American Diabetic Association; HgA1c, hemoglobin A1C; CBC, complete blood count; ECG, electrocardiogram. Adapted from The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23:S4\u2013S42. Table 9.11 Patient Guidelines for Treatment of Type 2 Diabetes Initiate an ADA reducing diet (50% CHO, 30% fat, 20% protein, high fiber) with three meals a day. Maintain ideal body weight or to reduce weight by 5% to 15% in 3 months if obese."
        },
        {
            "id": "InternalMed_Harrison_21928",
            "title": "InternalMed_Harrison",
            "content": "The natural history of diabetic nephropathy in patients with types 1 and 2 diabetes is similar. However, since the onset of type 1 diabetes is readily identifiable and the onset of type 2 diabetes is not, a patient newly diagnosed with type 2 diabetes may present with advanced diabetic nephropathy. At the onset of diabetes, renal hypertrophy and glomerular hyperfiltration are present. The degree of glomerular hyperfiltration correlates with the subsequent risk of clinically significant nephropathy. In the approximately 40% of patients with diabetes who develop diabetic nephropathy, the earliest manifestation is an increase in albuminuria detected by sensitive radioimmunoassay (Table 338-1). Albuminuria in the range of 30\u2013300 mg/24 h is called microalbuminuria. Microalbuminuria appears 5\u201310 years after the onset of diabetes. It is currently recommended to test patients with type 1 disease for microalbuminuria 5 years after diagnosis of diabetes and yearly thereafter and, because the"
        },
        {
            "id": "InternalMed_Harrison_27816",
            "title": "InternalMed_Harrison",
            "content": "IGT who are at very high risk for progression to diabetes (age <60 years, BMI \u226535 kg/m2, family history of diabetes in first-degree relative, and women with a history of GDM). Individuals with IFG, IGT, or an HbA1c of 5.7\u20136.4% should be monitored annually to determine if diagnostic criteria for diabetes are present."
        },
        {
            "id": "Gynecology_Novak_904",
            "title": "Gynecology_Novak",
            "content": "Table 9.10 Physician Guidelines in the Therapy of Diabetes Mellitus Establish diagnosis and classify type of diabetes mellitus (DM). The oral glucose tolerance test (OGTT) is not recommended for routine clinical use because of its higher cost, time requirement, and limited reproducibility. Initiate diabetes education classes to learn blood glucose monitoring and diabetes medications; to learn signs, symptoms, and complications; and to learn how to manage sick days. Place patient on ADA diet with appropriate caloric, sodium, and lipid restrictions. Establish cardiac risk factors, kidney function (serum creatinine, urine for microalbuminuria). If neuropathy is present, refer to a neurologist. Establish extent of fundoscopic lesion (refer to ophthalmologist as needed). Check feet and toenails at least once a year and refer to a foot specialist. Use finger-stick blood glucose for daily diabetic control. Follow chronic glycemic control by HgA1c every 2 to 3 months in the office."
        },
        {
            "id": "Obstentrics_Williams_6598",
            "title": "Obstentrics_Williams",
            "content": "its onset. The most important among these are type 2 diabetes, dyslipidemia, and hypertension, which are constituents of the metabolic syndrome. Criteria to define this syndrome are found in Table 48-1 (Alberti, 2009). Waist circumference is the preferred measurement for screening, but any three of five factors listed are suicient to diagnosis the metabolic syndrome. N otably, most patients with type 2 diabetes have metabolic syndrome according to these criteria. Also, obese women with hypertension typically demonstrate elevated plasma insulin levels. hese are even higher in women with central obesity (Fu, 2015). he National Health Nutrition Examination Survey (NHANES) of the Centers for Disease Control and Prevention documented an overall 34-percent prevalence of the metabolic syndrome in the United States by 2012 (Moore, 2017). As expected, the prevalence rose with age. It was 20 percent for those aged 18 to 29 years and was 36 percent for those aged 30 to 49 years."
        },
        {
            "id": "InternalMed_Harrison_27838",
            "title": "InternalMed_Harrison",
            "content": "The morbidity and mortality rates of DM-related complications (Chap. 419) can be greatly reduced by timely and consistent surveillance procedures (Table 418-1). These screening procedures are indicated for all individuals with DM, but many individuals with diabetes do not receive comprehensive diabetes care. A comprehensive eye examination should be performed by a qualified optometrist or ophthalmologist. Because many individuals with type 2 DM have had asymptomatic diabetes for several years before diagnosis, the American Diabetes Association (ADA) recommends the following ophthalmologic examination schedule: (1) individuals with type 1 DM should have an initial eye examination within 5 years of diagnosis, (2) individuals with type 2 DM should have an initial eye examination at the time of diabetes diagnosis, (3) women with DM who are pregnant or contemplating pregnancy should have an eye examination prior to conception and during the first trimester, and (4) if eye exam is normal,"
        },
        {
            "id": "Obstentrics_Williams_7950",
            "title": "Obstentrics_Williams",
            "content": "Based largely on these two landmark studies, the U.S. Preventive Sevices Task Force (2014) now recommends universal screening in low-risk women after 24 weeks' gestation. However, the Task Force concluded that evidence is insuicient to assess the balance of benefits versus harms of screening before 24 weeks. For screening, the optimal OGTT ro identiy gestational diabetes has not been agreed upon. The World Health Organization (2013) and the ADA (2017a) recommend the tions listed are met or exceeded for a positive diagnosis. (Serum glucose level. dSerum or plasma glucose level. NDDG = National Diabetes Data Group. Data from American Diabetes Association, 201n7a; Ferrara, 2002."
        },
        {
            "id": "InternalMed_Harrison_322",
            "title": "InternalMed_Harrison",
            "content": "Many patients see a physician for ongoing care of chronic illnesses, and this visit provides an opportunity to include a \u201cmeasure of prevention\u201d for other health problems. For example, a patient seen for management of hypertension or diabetes can have breast cancer screening incorporated into one visit and a discussion about colon cancer screening at the next visit. Other patients may respond more favorably to a clearly defined visit that addresses all relevant screening and prevention interventions. Because of age or comorbidities, it may be appropriate with some patients to abandon certain screening and prevention activities, although there are fewer data about when to \u201csunset\u201d these services. For many screening tests, the benefit of screening does not accrue until 5 to 10 years of follow-up, and there are generally few data to support continuing screening for most diseases past age 75. In addition, for patients with advanced diseases and limited life expectancy, there is"
        },
        {
            "id": "InternalMed_Harrison_27823",
            "title": "InternalMed_Harrison",
            "content": "APPROACH TO THE PATIENT: Once the diagnosis of DM is made, attention should be directed to symptoms related to diabetes (acute and chronic) and classifying the type of diabetes. DM and its complications produce a wide range of symptoms and signs; those secondary to acute hyperglycemia may occur at any stage of the disease, whereas those related to chronic hyperglycemia begin to appear during the second decade of hyperglycemia (Chap. 419). Individuals with previously undetected type 2 DM may present with chronic complications of DM at the time of diagnosis. The history and physical examination should assess for symptoms or signs of acute hyperglycemia and should screen for the chronic complications and conditions associated with DM."
        },
        {
            "id": "InternalMed_Harrison_27832",
            "title": "InternalMed_Harrison",
            "content": "The laboratory assessment should first determine whether the patient meets the diagnostic criteria for DM (Table 417-2) and then assess the degree of glycemic control (Chap. 418). In addition to the standard laboratory evaluation, the patient should be screened for DM-associated conditions (e.g., albuminuria, dyslipidemia, thyroid dysfunction). The classification of the type of DM may be facilitated by laboratory assessments. Serum insulin or C-peptide measurements often do not distinguish type 1 from type 2 DM, but a low C-peptide level confirms a patient\u2019s need for insulin. Many individuals with new-onset type 1 DM retain some C-peptide production. Measurement of islet cell antibodies at the time of diabetes onset may be useful if the type of DM is not clear based on the characteristics described above. Diabetes mellitus: management Alvin C. Powers"
        },
        {
            "id": "Obstentrics_Williams_7943",
            "title": "Obstentrics_Williams",
            "content": "OGI = oral glucose tolerance test. Data from International Association of Diabetes and Pregnancy Study Groups, 2010. Workshop Conferences on Gestational Diabetes endorsed use ofselective screening criteria shown in Table 57-12. Conversely, the American College of Obstetricians and Gynecologists (2017a) recommends universal screening of pregnant women using a laboratory-based blood glucose test. It is suggested that attempts to identiy the 10 percent of women who should not be screened would add unnecessary complexity. Screening should TABLE 57-12. Risk-Based Recommended Screening Strategy for Detecting GDMa GDM risk assessment: should be ascertained at the first prenatal visit Low Risk: Blood glucose testing not routinely required if all the following are present: Member of an ethnic group with a low prevalence of GDM No known diabetes in first-degree relatives No history of abnormal glucose metabolism No history of poor obstetrical outcome"
        },
        {
            "id": "Biochemistry_Lippincott_1850",
            "title": "Biochemistry_Lippinco",
            "content": "Prognosis: Diabetes is the seventh leading cause of death by disease in the United States. Individuals with diabetes have a reduced life expectancy relative to those without diabetes. Nutrition Nugget: Monitoring total intake of carbohydrates is primary in blood glucose control. Carbohydrates should come from whole grains, vegetables, legumes, and fruits. Low-fat dairy products and nuts and fish rich in \u03c9-3 fatty acids are encouraged. Intake of saturated and trans fats should be minimized. Genetics Gem: Autoimmune destruction of pancreatic \u03b2 cells is characteristic of T1D. Of the genetic loci that confer risk for T1D, the human-leukocyte antigen (HLA) region on chromosome 6 has the strongest association. The majority of genes in the HLA region are involved in the immune response. Review Questions: Choose the ONE best answer. RQ1. Which of the following statements concerning T1D is correct?"
        },
        {
            "id": "InternalMed_Harrison_27751",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 417-2 Worldwide prevalence of diabetes mellitus. Global estimate is 382 million indi-viduals with diabetes. Regional estimates of the number of individuals with diabetes (20\u201379 years of age) are shown (2013). (Used with permission from the IDF Diabetes Atlas, the International Diabetes Federation, 2013.) million), India (65.1 million), United States (24.4 million), Brazil (11.9 million), and the Russian Federation (10.9 million). Up to 80% of individuals with diabetes live in low-income or medium-income countries. In the most recent estimate for the United States (2012), the Centers for Disease Control and Prevention (CDC) estimated that 9.3% of the population had diabetes (~28% of the individuals with diabetes were undiagnosed; globally, it is estimated that 50% of individuals may be undiagnosed). The CDC estimated that the incidence and prevalence of diabetes doubled from 1990\u20132008, but appears to have plateaued from 2008\u20132012. DM increases with age. In 2012, the prevalence"
        },
        {
            "id": "Obstentrics_Williams_7941",
            "title": "Obstentrics_Williams",
            "content": "Despite almost 50 years of research, there is still no agreement regarding optimal gestational diabetes screening. The diiculty in achieving consensus is underscored by the controversy following publication of the single-step approach espoused by the International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) and shown in Table 57-11. his strategy was greatly influenced by results of the Hypoglycemia and Pregnancy Outcomes (HAPO) Study, described later. Although the ADA (2017 a) supports this new scheme, the American College of Obstetricians and Gynecologists (2017a) continues to recommend a two-step approach to screen and diagnose gestational diabetes. Similarly, the NIH Consensus Development Conference in 2013 concluded that evidence is insuicient to adopt a one-step approach."
        },
        {
            "id": "Obstentrics_Williams_7945",
            "title": "Obstentrics_Williams",
            "content": "Reproduced with permission from Metzger BE, Coustan DR, the Organizing Committee: Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus, Diabetes Care. 1998 Aug; 21 SuppIn2:B161n-B167. TABLE 57-13. Diagnosis of GDM Using Threshold women not known to have glucose intolerance earlier in preg nancy. This 50-g screening test is followed by a dianostic 100-g, Tolerance Testa,b 3-hour oral glucose tolerance test (OGT) if screening results meet or exceed a predetermined plasma glucose concentration. For the 50-g screen, the plasma glucose level is measured 1 hour ater a 50-g oral glucose load without regard to the time"
        },
        {
            "id": "InternalMed_Harrison_27752",
            "title": "InternalMed_Harrison",
            "content": "be undiagnosed). The CDC estimated that the incidence and prevalence of diabetes doubled from 1990\u20132008, but appears to have plateaued from 2008\u20132012. DM increases with age. In 2012, the prevalence of DM in the United Sates was estimated to be 0.2% in individuals age <20 years and 12% in individuals age >20 years. In individuals age >65 years, the prevalence of DM was 26.9%. The prevalence is similar in men and women throughout most age ranges (14% and 11%, respectively, in individuals age >20 years). Worldwide, most individuals with diabetes are between the ages of 40 and 59 years."
        },
        {
            "id": "InternalMed_Harrison_28025",
            "title": "InternalMed_Harrison",
            "content": "As part of comprehensive diabetes care (Chap. 418), albuminuria should be detected at an early stage when effective therapies can be instituted. Because some individuals with type 1 or type 2 DM have a decline in GFR in the absence of albuminuria, annual measurement of the serum creatinine to estimate GFR should also be performed. FIGURE 419-4 Screening for microalbuminuria should be performed in patients with type 1 diabetes for \u22655 years, in patients with type 2 diabetes, and during pregnancy. Non-diabetes-related conditions that might increase microalbuminuria are urinary tract infection, hematuria, heart failure, febrile illness, severe hyperglycemia, severe hypertension, and vigorous exercise. (Adapted from RA DeFranzo, in Therapy for Diabetes Mellitus and Related Disorders, 3rd ed. American Diabetes Association, Alexandria, VA, 1998.)"
        },
        {
            "id": "InternalMed_Harrison_28050",
            "title": "InternalMed_Harrison",
            "content": "The American Heart Association has designated DM as a \u201cCHD risk equivalent,\u201d and type 2 DM patients without a prior MI have a similar risk for coronary artery\u2013related events as nondiabetic individuals who have had a prior MI. However, the cardiovascular risk assessment in type 2 DM should encompass a more nuanced approach. Cardiovascular risk is lower and not equivalent in a younger individual with a brief duration of type 2 DM compared to an older individual with long-standing type 2DM. Because of the extremely high prevalence of underlying CVD in individuals with diabetes (especially in type 2 DM), evidence of atherosclerotic vascular disease (e.g., cardiac stress test) should be sought in an individual with diabetes who has symptoms suggestive of cardiac ischemia or peripheral or carotid arterial disease. The screening of asymptomatic individuals with diabetes for CHD, even with a risk-factor scale, is not recommended because recent studies have not shown a clinical benefit. The"
        },
        {
            "id": "InternalMed_Harrison_27766",
            "title": "InternalMed_Harrison",
            "content": "additional risk factor for diabetes (Table 417-3). In contrast to type 2 DM, a long asymptomatic period of hyperglycemia is rare prior to the diagnosis of type 1 DM. A number of immunologic markers for type 1 DM are becoming available (discussed below), but their routine use outside a clinical trial is discouraged, pending the identification of clinically beneficial interventions for individuals at high risk for developing type 1 DM."
        },
        {
            "id": "InternalMed_Harrison_28066",
            "title": "InternalMed_Harrison",
            "content": "The optimal therapy for foot ulcers and amputations is prevention through identification of high-risk patients, education of the patient, and institution of measures to prevent ulceration. High-risk patients should be identified during the routine, annual foot examination performed on all patients with DM (see \u201cOngoing Aspects of Comprehensive Diabetes Care\u201d in Chap. 418). If the monofilament test or one of the other tests is abnormal, the patient is diagnosed with loss of protective sensation (LOPS; Chap. 417). Providers should consider screening for asymptomatic PAD in individuals >50 years of age who have diabetes and other risk factors using anklebrachial index testing in high-risk individuals (Chap. 302). Patient education should emphasize (1) careful selection of footwear, (2) daily inspection of the feet to detect early signs of poor-fitting footwear or minor trauma, (3) daily foot hygiene to keep the skin clean and moist, (4) avoidance of self-treatment of foot abnormalities"
        },
        {
            "id": "Obstentrics_Williams_7989",
            "title": "Obstentrics_Williams",
            "content": "Recommendations for postpartum evaluation are based on the 50-percent likelihood of women with gestational diabetes developing overt diabetes within 20 years (O'Sullivan, 1982). The Fifth International Workshop Conference on Gestational Diabetes recommended that women diagnosed with gestational diabetes undergo postpartum evaluation with a 75-g OGTT (Metzger, 2007). These recommendations are shown in Table 57-14 along with the classification scheme of the ADA (20 17b). Eggleston and colleagues (2016) reviewed insurance claim data from 2000 to 2013 and found that only 24 percent of women with a pregnancy complicated by gestational diabetes underwent postpartum screening within a year, and less than half of those underwent a 75-g OGTT. he American College TABLE 57-14. Fifth International Workshop-Conference: Metabolic Assessments Recommended after Pregnancy with Fasting or random plasma glucose 75-g, 2-hr OGI 75-g, 2-hr OGTI 75-g, 2-hr OGTI 75-g, 2-hr OGTI"
        },
        {
            "id": "InternalMed_Harrison_295",
            "title": "InternalMed_Harrison",
            "content": "This chapter will review the basic principles of screening and prevention in the primary care setting. Recommendations for specific disorders such as cardiovascular disease, diabetes, and cancer are provided in the chapters dedicated to those topics. The basic principles of screening populations for disease were published by the World Health Organization in 1968 (Table 4-1). In general, screening is most effective when applied to relatively common disorders that carry a large disease burden (Table 4-2). The five leading causes of mortality in the United States are heart diseases, malignant neoplasms, accidents, cerebrovascular diseases, and chronic obstructive pulmonary disease. Thus, many screening strategies are targeted at these conditions. From a global health perspective, these conditions are priorities, but malaria, malnutrition, AIDS, tuberculosis, and violence also carry a heavy disease burden (Chap. 2). challenging for some common diseases. For example, although"
        },
        {
            "id": "InternalMed_Harrison_21929",
            "title": "InternalMed_Harrison",
            "content": "years after the onset of diabetes. It is currently recommended to test patients with type 1 disease for microalbuminuria 5 years after diagnosis of diabetes and yearly thereafter and, because the time of onset of type 2 diabetes is often unknown, to test type 2 patients at the time of diagnosis of diabetes and yearly thereafter."
        },
        {
            "id": "InternalMed_Harrison_27837",
            "title": "InternalMed_Harrison",
            "content": "Diabetes Mellitus: Management and Therapies guiDElinES foR ongoing, ComPREHEnSivE mEDiCAl CARE foR PATiEnTS wiTH DiAbETES Self-monitoring of blood glucose (individualized frequency) \u2022 HbA1c testing (2\u20134 times/year) Eye examination (annual or biannual; Chap. 419) Chap. 419) Screening for diabetic nephropathy (annual; Chap. 419) Lipid profile and serum creatinine (estimate GFR) (annual; Chap. 419) Consider antiplatelet therapy (Chap. 419) Abbreviations: GFR, glomerular filtration rate; HbA1c, hemoglobin A1c. for this comprehensive level of diabetes care. The treatment goals for patients with diabetes are summarized in Table 418-2 and should be individualized."
        },
        {
            "id": "InternalMed_Harrison_27755",
            "title": "InternalMed_Harrison",
            "content": "Diabetes is a major cause of mortality, but several studies indicate that diabetes is likely underreported as a cause of death. In the United States, diabetes was listed as the seventh leading cause of death in 2010. A recent estimate suggested that diabetes was responsible for almost 5.1 million deaths or 8% of deaths worldwide in 2013. In 2013, it was estimated that $548 billion or 11% of health care expenditures worldwide were spent on individuals with diabetes. CRiTERiA foR THE DiAgnoSiS of DiAbETES mElliTuS \u2022 Symptoms of diabetes plus random blood glucose concentration \u226511.1 mmol/L (200 mg/dL)a or Fasting plasma glucose \u22657.0 mmol/L (126 mg/dL)b or"
        },
        {
            "id": "Gynecology_Novak_903",
            "title": "Gynecology_Novak",
            "content": "Oral Hypoglycemic Agents Oral hypoglycemic agents are recommended for many type 2 diabetic patients. The first oral hypoglycemic agents introduced were first-and second-generation sulfonylureas. Other classes of drugs that have different effects in patients with type 2 diabetes\u2014such as biguanides, thiazolidinediones, alpha-glucosidase inhibitors, and insulin secretagogues\u2014were introduced. The mode of action of sulfonylureas is based on two different mechanisms: (i) enhanced insulin secretion from the pancreas, and (ii) an extrapancreatic effect that is poorly understood. Endogenous insulin secretion (as measured by C-peptide) is necessary for oral hypoglycemic agents to work. If the fasting blood glucose on an adequate diabetic diet is greater than 250 mg/dL, there is little effect. Frequent evaluation to monitor control (every 3 to 4 months) is important. If glucose levels cannot be controlled with oral hypoglycemic agents (i.e., sulfonylureas) or other"
        },
        {
            "id": "Gynecology_Novak_795",
            "title": "Gynecology_Novak",
            "content": "Most patients with hypertension will require two or more antihypertensive medications to achieve optimal blood pressure control less than 140/90 or less than 130/80 mm Hg for patients with diabetes or kidney disease, respectively. There is an increased use of cholesterol-lowering drugs, including the \u201cstatins,\u201d a class of drugs that lower cholesterol by blocking a liver enzyme necessary to produce cholesterol, and they are very effective in reducing the risk of heart attacks and deaths. Type 2 diabetes is frequently not diagnosed until complications appear, and approximately one-third of all people with diabetes may be undiagnosed: individuals at risk should be screened and a comprehensive plan of care initiated for those diagnosed with diabetes."
        },
        {
            "id": "InternalMed_Harrison_21709",
            "title": "InternalMed_Harrison",
            "content": "In contrast to the natural decline and successful eradication of many devastating infectious diseases, there is rapid growth in the prevalence of metabolic and vascular disease in developing countries. Diabetes mellitus is becoming increasingly prevalent in these countries, perhaps due in part to change in dietary habits, diminished physical activity, and weight gain. Therefore, it follows that there will be a proportionate increase in vascular and renal disease. Health care agencies must plan for improved screening for early detection, prevention, and treatment plans in these nations and must start considering options for improved availability of renal replacement therapies."
        },
        {
            "id": "InternalMed_Harrison_10756",
            "title": "InternalMed_Harrison",
            "content": "STD care and management begin with risk assessment and proceed to clinical assessment, diagnostic testing or screening, treatment, and prevention. Indeed, the routine care of any patient begins with risk assessment (e.g., for risk of heart disease, cancer). STD/HIV risk assessment is important in primary care, urgent care, and emergency care settings as well as in specialty clinics providing adolescent, HIV/ AIDS, prenatal, and family planning services. STD/HIV risk assessment guides detection and interpretation of symptoms that could reflect an STD; decisions on screening or prophylactic/preventive treatment; risk reduction counseling and intervention (e.g., hepatitis B vaccination); and treatment of partners of patients with known infections. Consideration of routine demographic data (e.g., gender, age, area of residence) is a simple first step in STD/HIV risk assessment. For example, national guidelines strongly recommend routine screening of sexually active females \u226425 years of"
        },
        {
            "id": "InternalMed_Harrison_27993",
            "title": "InternalMed_Harrison",
            "content": "Diabetes-related complications affect many organ systems and are responsible for the majority of morbidity and mortality associated with the disease. Strikingly, in the United States, diabetes is the leading cause of new blindness in adults, renal failure, and nontraumatic lower extremity amputation. Diabetes-related complications usually do not appear until the second decade of hyperglycemia. Because type 2 diabetes mellitus (DM) often has a long asymptomatic period of hyperglycemia before diagnosis, many individuals with type 2 DM have complications at the time of diagnosis. Fortunately, many of the diabetes-related complications can be prevented or delayed with early detection, aggressive glycemic control, and efforts to minimize the risks of complications."
        },
        {
            "id": "InternalMed_Harrison_28051",
            "title": "InternalMed_Harrison",
            "content": "arterial disease. The screening of asymptomatic individuals with diabetes for CHD, even with a risk-factor scale, is not recommended because recent studies have not shown a clinical benefit. The absence of chest pain (\u201csilent ischemia\u201d) is common in individuals with diabetes, and a thorough cardiac evaluation should be considered prior to major surgical procedures."
        }
    ],
    "scores": [
        0.02905070606016072,
        0.024137478682933228,
        0.02282551332352532,
        0.022693253615798298,
        0.020701878766394895,
        0.01889405217790399,
        0.018614718614718615,
        0.018543956043956044,
        0.017496229260935144,
        0.017391304347826087,
        0.017241379310344827,
        0.017185900248647065,
        0.016680339075745145,
        0.016592171204117566,
        0.0164021164021164,
        0.01632680261228842,
        0.01620097074642529,
        0.01614583333333333,
        0.016,
        0.015944498539435248,
        0.015040995193666949,
        0.014699173805058544,
        0.01466795615731786,
        0.014644569522618304,
        0.014626986537098896,
        0.01453833066969119,
        0.014169535498677843,
        0.013929053402737613,
        0.013763197586726998,
        0.01367386669138778,
        0.013433756166314306,
        0.013005050505050506
    ]
}